PartnershipJul 7, 2026, 07:37 AM
Vivani Medical Partners with Novo Nordisk to Evaluate Semaglutide Implant
AI Summary
Vivani Medical, Inc. announced a new agreement with Novo Nordisk for the evaluation of NPM-139, Vivani's semaglutide drug implant for chronic weight management. This agreement does not include exclusivity provisions for the implant or Vivani's NanoPortal™ technology. Separately, Vivani plans to initiate a Phase 1, first-in-human study for NPM-139 in mid-2026, comparing it against Wegovy® injections.
Key Highlights
- Vivani Medical signed a new agreement with Novo Nordisk.
- Novo Nordisk will evaluate Vivani's semaglutide drug implant, NPM-139.
- NPM-139 is being developed for chronic weight management.
- The agreement has no exclusivity provisions for NPM-139 or NanoPortal technology.
- Vivani expects to initiate a Phase 1 study for NPM-139 in mid-2026.
- The Phase 1 study will use Wegovy® injections as an active comparator.
Price Impact
More from VANI